Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

FibroGen, Inc - Common Stock (NQ:FGEN)

0.3085 -0.0005 (-0.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about FibroGen, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Curious about the stocks that are showing activity after the closing bell on Thursday?
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Earnings Scheduled For May 12, 2025
Via Benzinga
A Preview Of FibroGen's Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For FibroGen
Via Benzinga
Earnings Scheduled For March 17, 2025
Via Benzinga
What's going on in today's pre-market session
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
On Friday, there are stocks with unusual volume. Let's take a look.
On Friday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
What's going on in today's session
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
Thursday's session: most active stocks
Curious about the most active stocks on Thursday? Find out which stocks are dominating the market action! 
Via Chartmill
Top movers in Thursday's session
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its CD46-targeting ADC and PET imaging agent. 
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Stay updated with the stocks that are on the move in today's pre-market session.
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q2 2024
FGEN stock results show that FibroGen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher
Via Benzinga
Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program
FibroGen reports topline results from late-stage trials of pamrevlumab for pancreatic cancer, failing to meet the primary endpoint of overall survival. 
Via Benzinga
Ground Cinnamon Recalls: What to Know as FDA Issues Alert Over Lead Levels
New ground cinnamon recalls are in effect as the FDA warns consumers about increased lead levels in some of these products. 
Via InvestorPlace
Topics Product Recall
Exposures Legal Product Safety
Why Are Chip Stocks Up Today?
Chip stocks are up today and investors wondering why will find all of the news explaining the rally in the sector on Wednesday. 
Via InvestorPlace
FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts
FibroGen layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why is Macrogenics (MGNX) Stock Down 28% Today?
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial. 
Via InvestorPlace
Why Is FibroGen (FGEN) Stock Down 44% Today?
FibroGen stock is down on Wednesday as FGEN investors react to the company's failed clinical trials for its pancreatic cancer treatment. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning! 
Via InvestorPlace
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What's Going On With FibroGen Stock Tuesday?
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial... 
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.